Small Molecule Injectable Drugs Market
The term ‘small molecule’ or low-molecular-weight organic compound means that the drug can be administered orally or that it can be injected through parenteral routes. Small-molecule injectable drugs are used in the treatment of oncology disorders, infectious diseases, blood diseases, and cardiovascular diseases.
Moreover, the small-molecule drugs are very easy to synthesize and can be produced in large quantities and also these drugs are very simple to manufacture, which leads to strong generic competition among market players. As small molecules typically work by mimicking biological substrates or allosterically targeting hydrophobic pockets of proteins, certain biological targets may not be druggable. Many bacterial and cancer cells have developed resistance to small-molecule drugs through mechanisms such as chemoenzymatic modifications, efflux pumps, drug target mutations, etc.
Market Dynamics
Market players are initiating production of injectable drugs in the new manufacturing facility, which is expected to drive growth of the global small molecule injectable drugs, over the forecast period. For instance, in August 2018, Pfizer Inc., a pharmaceutical and Biotechnology Corporation, announced injectable production at Portage in Kalamazoo, Michigan. The plant will enable Pfizer to produce injectable medicines for patients suffering from chronic diseases such as oncology, across the globe, as well as supporting the company’s supply capacity and production.
Key players are involved in receiving approvals from regulatory authorities for new small molecule injectable drugs. This is expected to drive growth of the global small molecule injectable drugs market, over the forecast period. For instance in October 2020, Aurobindo Pharma Ltd., a pharmaceutical company, announced that they received approval from the U.S. Food and Drug Administration for its generic acetaminophen injection. It is indicated for the treatment of pain in pediatric patients and adults.
Moreover, in 2018, Aurobindo Pharma Ltd. announced that they received approval from U.S. Food and Drug Administration to manufacture and market Vecuronium Bromide Injection, 10mg and 20mg for the U.S. markets. This drug is utilized as a part of general anesthesia to give skeletal muscle relaxation during mechanical ventilation or surgery.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 37 market data tables and 45 figures on "Global Small Molecule Injectable Drugs Market” - Forecast to 2030.
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowWe help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request Discount
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients